Swiss dermatology company Galderma announced that it had agreed to acquire ZO Skin Health, a skincare brand focused on sales to physicians in the United States, for an enterprise value of $1.5 billion.
Swiss company Galderma (ガルデルマ) announced on 14 October that it had agreed to acquire ZO Skin Health for $1.5 billion.
The acquisition is intended to strengthen its skincare business for medical institutions by leveraging the brand strength of ZO Skin Health, which operates in both the aesthetic injectables and skincare markets.
Galderma said it plans to integrate the business portfolio by incorporating ZO Skin Health and combining it with its existing brands.
The acquisition was reported by the cosmetics industry publication Shogyo Nippo, and further information on pending decisions and the completion date is expected.